Methods of treating central nervous system disorders with aryl substituted olefinic amine compounds
AssigneeTargacept, Inc.
InventorsWilliam Scott Caldwell, Gary Maurice Dull, Merouane Bencherif, Patrick Michael Lippiello
Life of this patent
Estimating the term…
Abstract
Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound. Exemplary compounds include, (E)-N-methyl-4-[3-(5-isopropoxypyridin)yl]-3-buten-1-amine, and (E)-N-methyl-4-[3-(5-methoxymethylpyridin)yl]-3-buten-1-amine.
Claims16
A method for providing prevention or treatment of a central nervous system disorder comprising administering to a subject in need thereof, an effective amount of a compound of the formula:
- wherein X is C—CH2—OR′ wherein R′ is C1-C5 alkyl;
- E′ is hydrogen or C1-C5 alkyl or halo substituted C1-C5 alkyl;
- E″ is C1-C5 alkyl or halo substituted C1-C5 alkyl;
- either Z′ or Z″ is C1-C7 with the other selected from the group consisting of hydrogen, C1-C5 alkyl, aryl rings, and cycloalkyl;
- A, A′ and A″ are each individually selected from the group consisting of hydrogen, C1-C7 alkyl, and halo;
- m is 0 or 1;
- n is 1, 2, 3, 4, 5, 6, 7 or 8;
- p is 0 or 1 with the proviso that when m or p or both are 0 then E′ or E″ is hydrogen;
- and the wavy line in the structure represents a cis (Z) or trans (E) form of the compound;
- wherein said compound is administered in an amount effective to prevent or treat said central nervous system disorder.
A method for providing prevention or treatment of a central nervous system disorder comprising administering to a subject in need thereof, an effective amount of a compound of the formula:
- wherein X is COCH(CH3)2;
- E′ is hydrogen or C1-C5 alkyl or halo substituted C1-C5 alkyl;
- E″ is C1-C5 alkyl or halo substituted C1-C5 alkyl;
- either Z′ or Z″ is C1-C7 with the other selected from the group consisting of hydrogen, C1-C5 alkyl, aryl rings, and cycloalkyl;
- A, A′ and A″ are each individually selected from the group consisting of hydrogen, C1-C7 alkyl, and halo;
- m is 0 or 1 n is 1, 2, 3, 4, 5, 6, 7 or 8;
- p is 0 or 1 with the proviso that when m or p or both are 0 then E′ or E″ is hydrogen;
- and the wavy line in the structure represents a cis (Z) or trans (E) form of the compound;
- wherein said compound is administered in an amount effective to prevent or treat said central nervous system disorder.
Dependencies are inferred from the claim text.